518 related articles for article (PubMed ID: 22502864)
1. Treatment of seasonal allergic rhinoconjunctivitis with a once-daily SQ-standardized grass allergy immunotherapy tablet.
Nelson H; Lehmann L; Blaiss MS
Curr Med Res Opin; 2012 Jun; 28(6):1043-51. PubMed ID: 22502864
[TBL] [Abstract][Full Text] [Related]
2. Allergy immunotherapy tablet: Grazax® for the treatment of grass pollen allergy.
Senna GE; Calderon M; Milani M
Expert Rev Clin Immunol; 2011 Jan; 7(1):21-7. PubMed ID: 21162646
[TBL] [Abstract][Full Text] [Related]
3. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.
Reich K; Gessner C; Kroker A; Schwab JA; Pohl W; Villesen H; Wüstenberg E; Emminger W
Clin Ther; 2011 Jul; 33(7):828-40. PubMed ID: 21741092
[TBL] [Abstract][Full Text] [Related]
4. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis.
Durham SR; Yang WH; Pedersen MR; Johansen N; Rak S
J Allergy Clin Immunol; 2006 Apr; 117(4):802-9. PubMed ID: 16630937
[TBL] [Abstract][Full Text] [Related]
5. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis.
Dahl R; Stender A; Rak S
Allergy; 2006 Feb; 61(2):185-90. PubMed ID: 16409194
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis.
Frew AJ; Powell RJ; Corrigan CJ; Durham SR;
J Allergy Clin Immunol; 2006 Feb; 117(2):319-25. PubMed ID: 16461133
[TBL] [Abstract][Full Text] [Related]
7. Design and recruitment for the GAP trial, investigating the preventive effect on asthma development of an SQ-standardized grass allergy immunotherapy tablet in children with grass pollen-induced allergic rhinoconjunctivitis.
Valovirta E; Berstad AK; de Blic J; Bufe A; Eng P; Halken S; Ojeda P; Roberts G; Tommerup L; Varga EM; Winnergard I;
Clin Ther; 2011 Oct; 33(10):1537-46. PubMed ID: 21999887
[TBL] [Abstract][Full Text] [Related]
8. Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial.
Pfaar O; Wolf H; Klimek L; Schnitker J; Wüstenberg E
Clin Ther; 2012 Oct; 34(10):2072-81. PubMed ID: 23063373
[TBL] [Abstract][Full Text] [Related]
9. Safety and tolerability of an SQ-standardized GRAss ALlergy immunotherapy tablet (GRAZAX®) in a real-life setting for three consecutive seasons - the GRAAL trial.
Wessel F; Chartier A; Meunier JP; Magnan A
Clin Drug Investig; 2012 Jul; 32(7):451-63. PubMed ID: 22594491
[TBL] [Abstract][Full Text] [Related]
10. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis.
Didier A; Worm M; Horak F; Sussman G; de Beaumont O; Le Gall M; Melac M; Malling HJ
J Allergy Clin Immunol; 2011 Sep; 128(3):559-66. PubMed ID: 21802126
[TBL] [Abstract][Full Text] [Related]
11. Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma.
Roberts G; Hurley C; Turcanu V; Lack G
J Allergy Clin Immunol; 2006 Feb; 117(2):263-8. PubMed ID: 16461125
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy.
Bufe A; Eberle P; Franke-Beckmann E; Funck J; Kimmig M; Klimek L; Knecht R; Stephan V; Tholstrup B; Weisshaar C; Kaiser F
J Allergy Clin Immunol; 2009 Jan; 123(1):167-173.e7. PubMed ID: 19130937
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of grass sublingual immunotherapy tablet, MK-7243: a large randomized controlled trial.
Maloney J; Bernstein DI; Nelson H; Creticos P; Hébert J; Noonan M; Skoner D; Zhou Y; Kaur A; Nolte H
Ann Allergy Asthma Immunol; 2014 Feb; 112(2):146-153.e2. PubMed ID: 24468255
[TBL] [Abstract][Full Text] [Related]
14. Randomized controlled trial of ragweed allergy immunotherapy tablet efficacy and safety in North American adults.
Nolte H; Hébert J; Berman G; Gawchik S; White M; Kaur A; Liu N; Lumry W; Maloney J
Ann Allergy Asthma Immunol; 2013 Jun; 110(6):450-456.e4. PubMed ID: 23706715
[TBL] [Abstract][Full Text] [Related]
15. Safety of specific sublingual immunotherapy with SQ standardized grass allergen tablets in children.
Ibañez MD; Kaiser F; Knecht R; Armentia A; Schöpfer H; Tholstrup B; Bufe A
Pediatr Allergy Immunol; 2007 Sep; 18(6):516-22. PubMed ID: 17680910
[TBL] [Abstract][Full Text] [Related]
16. Grass allergen tablet immunotherapy relieves individual seasonal eye and nasal symptoms, including nasal blockage.
Durham SR; Riis B
Allergy; 2007 Aug; 62(8):954-7. PubMed ID: 17620075
[TBL] [Abstract][Full Text] [Related]
17. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet.
Durham SR; Emminger W; Kapp A; Colombo G; de Monchy JG; Rak S; Scadding GK; Andersen JS; Riis B; Dahl R
J Allergy Clin Immunol; 2010 Jan; 125(1):131-8.e1-7. PubMed ID: 20109743
[TBL] [Abstract][Full Text] [Related]
18. [Sublingual immunotherapy in children with grass pollen induced allergic rhinoconjunctivitis].
Wolthers OD; Høst A; Frederiksen B; Halken S
Ugeskr Laeger; 2012 Aug; 174(35):1989-92. PubMed ID: 22929576
[TBL] [Abstract][Full Text] [Related]
19. Effect of grass pollen immunotherapy with Alutard SQ on quality of life in seasonal allergic rhinoconjunctivitis.
Powell RJ; Frew AJ; Corrigan CJ; Durham SR
Allergy; 2007 Nov; 62(11):1335-8. PubMed ID: 17714551
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of the SQ-standardized grass allergy immunotherapy tablet in mono- and polysensitized subjects.
Nelson H; Blaiss M; Nolte H; Würtz SØ; Andersen JS; Durham SR
Allergy; 2013 Feb; 68(2):252-5. PubMed ID: 23205670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
